—Pipeline
Pipeline
Clinical profile for RP-323
*Phase I Clinical Safety Studies completed. Not required to repeated Phase I when developing new indications using RP-323 but an abbreviated Phase IB might be required, a Phase I/II Study.
Clinical Pipeline
- Phase II Trials:
- Acute Myeloid Leukemia (AML)
- Hodgkin’s Lymphoma (HL)
- Acute Respiratory Distress Syndrome (ARDS)
- Preclinical Stage:
- Parkinson’s Disease (PD)